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Abstract: Following the rapid spread of SARS-CoV-2 worldwide, this article describes routine procedures and preventive 
measures for tissue banking and cell therapy in University Hospital Centre “Sestre milosrdnice” in the Republic of 
Croatia. This paper describes our current practice for preventing contamination and microbiological environmental 
monitoring of cleanrooms, the protection of healthcare personnel as well as patients from SARS-CoV-2. These measures 
are based on the recommendations obtained from the Ministry of Health of the Republic of Croatia, the Croatian Institute 
of Public Health and the European Centre for Disease Prevention and Control. We also present data on samples collected 
and treated in this period in comparison to normal work conditions before COVID-19. 
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INTRODUCTION 
The new SARS-CoV-2 virus causing the ongoing 
pandemic was isolated from a patient with pneumonia in 
Wuhan, the capital of Hubei Province, Central China in 
late 2019. As a highly contagious disease, COVID-19 is 
commonly manifested by fever (87.9%), dry cough 
(67.7%), fatigue (38.1%), vomiting (5.0%) and diarrhea 
(3.7%).1 In some cases, it can lead to more severe 
complications of the respiratory system such as dyspnea 
and/or hypoxemia or acute respiratory distress 
syndrome, with a slight chance of being lethal.2 On 
January 30th 2020, based on the high number of affected 
people and the global spread of SARS-CoV-2, the 
World Health Organization (WHO) confirmed the 
outbreak as a public health emergency of international 
interest. On March 11th 2020, WHO declared the 
COVID-19 outbreak a pandemic3 while on February 25th 
2020, the first patient with COVID-19 was identified in 
Zagreb, Croatia.4 
Coronaviruses are single-stranded RNA viruses with an 
approximate diameter of 0.08-0.12 μm, with four known 
types  α, β,  δ  and  γ.5  SARS-CoV-2 is  an  enveloped 
β-coronavirus with an estimated genome of 30 kb 
strands of RNA. It enters host cells by binding to the 
Angiotensin-Converting Enzyme 2 (ACE-2) receptor. 
This receptor is found in various tissues, including the 
conjunctiva and corneal epithelia. Ocular manifestations 
are not common in patients, but recent publications 
described how conjunctivitis could be the only symptom 
of COVID-19.6, 7 When the virus enters a cell, it firstly 
releases the viral envelope, after which the RNA is also 
released. Although this RNA virus originates from 
animals (bats are considered to be the potential source), 
it spreads relatively quickly and easily from an infected 
person to a healthy person. It is estimated that one 
infected person could infect 2-4 people in the situation 
of absence of physical distancing.8, 9 The incubation 
period is evaluated to be extended to 14 days with a 
median of 3 to 5 days.10, 11 Respiratory droplets are 




Molecular and Experimental Biology in Medicine, 2020, 3(2): 50-55 
 
small droplets (≤5 μm in diameter). Large droplets can 
only be transmitted over short distances as they usually 
fall rapidly to the surfaces that are touched, they are then 
transferred by hands onto the eyes, nose and mouth.12 
The diameter of large droplets produced by sneezing is 
around 100 μm.13 Small droplets can evaporate and 
remain suspended in air for some time and could be 
inhaled.  
Because tissue banking is a very important health 
service, the European Centre for Disease Prevention and 
Control (ECDC) accordingly provides information on 
the current risks which remain theoretical but cannot be 
completely excluded. The Ministry of Health of the 
Republic of Croatia issued a decree to temporarily stop 
harvesting allogeneic femoral heads, amniotic 
membranes and to suspend cultivation of autologous 
limbal cells and keratinocytes. The temporary stop of 
tissue harvesting was in place from March 23rd to May 
4th 2020. 
The COVID-19 pandemic has raised a new challenge for 
the management of quality control in tissue banking. 
Therefore, the aim of this article is to establish 






The Tissue and Cell Bank (Tissue Bank, TB) is a 
hospital unit of University Hospital Centre “Sestre 
milosrdnice” in the Republic of Croatia that has 
laboratories with cleanrooms and laboratory equipment. 
It also has the human resources required for donor 
evaluation, testing, processing, preservation, storage and 
distribution of human tissues for transplantations. The 
TB should be focused on good laboratory practice, good 
manufacturing practice and good clinical practice in 
accordance with national law, international standards, 
guidelines and recommendations. Our Department of 
Transfusion and Regenerative Medicine has established 
a unit for Quality Management (QM) that deals with 
aspects such as quality control in all segments of work 
in tissue banking, whilst traceability and document 
management are guaranteed. The main goal for QM in 
the field of tissue banking and cell therapy is to reduce 
the risk of disease transmission to tissue recipients.14 
 
 
Protection of healthcare personnel 
During the first two months of the pandemic, healthcare 
personnel (clinical transfusiologist, molecular biologist, 
molecular and processing biotechnologist, laboratory 
technicians) were working in two-week shifts. After 
that, routine work was continued with the full number of 
employees, working preferably at a physical distance of 
one meter or more, away from people to reduce the risk 
of spreading the virus with adequate protection 
according to the ECDC.15 It is necessary to prevent the 
SARS-CoV-2 virus from spreading between employees 
in offices by cancelling non-essential meetings and 
holding teleconferences. In case laboratory staff 
members develop symptoms of COVID-19, they should 
leave the workplace, self-isolate at home, contact a 
doctor and behave according to available information 
published by the epidemiology service of the Croatian 
Institute of Public Health.4 
 
 
Routine procedures and preventing contamination of 
cleanrooms 
Before entering the Laboratory for Tissue Engineering 
with cleanroom laboratory, staff must remove make-up, 
clothes, footwear, jewelry, wristwatches, cell phones, 
keys and wash their hands for at least 20-30 seconds. 
After that, hands should be dried and disinfected for 20-
30 seconds, which corresponds to the recommendations 
of ECDC.15 Hand washing with liquid soap (detergent 
with bactericidal, fungicidal and virucidal effects as an 
antiseptic, it also has a prolonged antimicrobial effect) 
and water is used for hygienic and surgical washing of 
hands and forearms as a measure of preventing the 
spread of microorganisms and thus the SARS-CoV-2. 
After hand washing and disinfection with 70 % ethyl 
alcohol, it is very important to use personal protective 
equipment such as a sterile face mask, cap, goggles, 
gloves, undergarment and overshoes, which are put on 
before entering a grade C cleanroom. Face masks 
provide a physical barrier between the mouth and nose 
of the staff and potential infection in their surroundings. 
They can block large-particle droplets that may contain 
viruses and bacteria, keeping them from entering 
people’s mouths and noses. Face masks may also help 
to reduce exposure of saliva and respiratory secretions 
to others. Avoiding talking during the processing should 
also be a preventive measure. Additional safety is gained 
by wearing clogs, sterile disposable suits and double 
sterile gloves in grade B cleanrooms (Figure 1). 
Additional preventive measures introduced during 
COVID-19 were a total of 37 intermediate clothing 
items (cleanroom undergarment, fabric 100% polyester) 
that were replaced. 
The Laboratory for Tissue Engineering (subordinated to 
the Bank) is organized and built according to the 
technology of cleanrooms in the manner of an existing 
HVAC system (Heating, Ventilating and Air 
Conditioning). The Laboratory is defined with two 
grade B cleanrooms (ISO class 6), one grade C room 
(ISO class 7) and one grade D room (ISO class 8). 
Surrounding cleanrooms with different grades have a 
pressure differential approximately 10 - 15 Pa, 
according to GMP. Particle size in the air is strictly 
controlled by using HEPA filters class H 14 which 
remove at least ≥ 99.995% of particles according to the 
European standard EN 1822-1.16 
Our Laboratory for Tissue Engineering is designed and 
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Figure 1. Healthcare personnel in protective clothing during work 
in Laboratory for Tissue Engineering 
 
 
introduction, generation and retention of concentrations 
of airborne particles inside the cleanrooms in line with 
ISO 14644-1:2015.17 Validation of cleanroom cleaning 
and maintenance of sterility within a particular class of 
a production space of the mentioned laboratory is a 
necessary precondition for safe tissue processing and/or 
cell cultivation. The source of contamination within the 
microbiologically controlled area of cleanrooms 
consists of various biological samples (placenta, skin, 
limbus biopsy and various cell cultures such as 
keratinocytes, limbal cells, dermal fibroblasts, 3T3 cell 
line, etc.), laboratory equipment, reagents, consumables 
and staff.  
Additional preventive measures introduced during 
COVID-19 were the new protocol for routine cleaning 
and disinfection of cleanrooms. In fact, we used the 
same disinfectants, but we introduced a new timetable. 
On the first day a sterile non-ionic detergent with low 
residues is used for cleaning and maintaining work 
surfaces in cleanrooms, while a 70% isopropyl alcohol 
(70% IPA) blended with deionized water was used to 
remove residues and for daily disinfection of surfaces. 
Moreover 70 % IPA has bactericide, fungicide and 
virucide efficacy (viruses with envelopes such as SARS-
CoV-2). On the second day a sporicidal agent (0.6 % 
hydrogen peroxide solutions) is used for disinfection of 
work surfaces (in spray or in the form of wet wipes), 
which is effective against bacteria and fungi. 
Furthermore, our plan is to periodically exchange other 
sporicidal agents (0.5% sodium hypochlorite solutions) 
because they are also effective against most 
microorganisms, including viruses, bacteria and fungi. 
 
 
Medical examination of allogeneic tissue donors 
The donors are examined, their medical documentation 
is reviewed, and they complete the Medical 
Questionnaire for a living allogeneic tissue donor which 
is all administered by a medical doctor associated to the 
TB. This medical questionnaire is also used for femoral 
head donors and placental donors which contains 
questions on whether they have had fever and 
respiratory symptoms such as cough and shortness of 
breath in the past 28 days, whether they have been in 
contact with an infected person or travelled in that 
period in a COVID-19 focus area. If donors of the 
femoral head have a test result for SARS-CoV-2 in their 
medical history, we will make a copy of the findings, 
and attach it to the donor's documentation in the TB. The 
recommended molecular test for SARS-CoV-2 infection 
is a real-time Reverse Transcriptase-Polymerase Chain 
Reaction (rRT-PCR). Placental donors should be pre-
tested for the presence of the SARS-CoV-2 virus. The 
diagnostic molecular test result should not be older than 
48 hours at the time of tissue collection. This testing is 
necessary to avoid possible contamination of clean areas 
and laboratory staff. 
 Additional preventive measures introduced for the 
safety of tissue banking during COVID-19 were that all 
allogeneic donors are required to leave a contact or cell 
phone number where they will be available. About 99% 
of symptomatic patients will develop/present symptoms 
before day 14.10 Therefore, after a minimum of 14 days 
of tissue storage, the responsible physician will contact 
the donor to check the onset of symptoms. In case of 
confirmation and / or suspicion of the disease, the tissue 
will not be used clinically and will be discarded in 
accordance with regulations. A telephone check of the 
donor will be entered into forms related to tissue donor 
quality control. 
Table 1 shows data on harvested femoral heads before 
and during COVID-19. As shown in Table 1, divergence 
in the number of collected femoral heads in these two 
trimesters is significant. It stems from a lower number 
of available donors due to the pandemic (number of 
patients that have undergone total hip arthroplasty was 
smaller). In the period from June 1st to September 30th 
none of the donors were COVID-19 positive and none 
of the tissues were lost due to this infection. 
 
 
Table 1. Number of harvested femoral heads before and during 
COVID-19 in 2020 
Period  Femoral heads  
01 Jan - 23 Mar 2020 33 




Medical examination of autologous tissue and cell 
donors 
Patients undergoing treatment with an Advanced 
Therapy Medicinal Product (ATMP), for which 
autologous cells (limbal or keratinocytes) will be grown 
in cultures, are checked for fever and respiratory 
symptoms such as cough and shortness of breath in the 
past 28 days. In addition, before taking and processing 
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rRT-PCR test which cannot be older than 48 hours. This 
additional measure was to prevent contamination of the 




Tissues must be quarantined until donor testing and data 
collection procedures are performed. Upon receipt of the 
collected tissues in our bank, it is necessary to document 
that the conditions of transport, packaging, labelling, 
attached documentation and samples meet the 
standard/recommended procedures. The TB has a 
Standard Operation Procedure (SOP) and specifications 
for checking the tissues and samples received. Data of 
the donor and the collection of tissues, swab and blood 
samples are reviewed by authorized laboratory workers.  
Tissues of allogeneic donors with COVID-19 positive 
epidemiological history would be safely discarded. This 
also applies to already stored tissues of allogeneic 
donors monitored for COVID-19-like symptoms within 
14 days after surgery. For autologous tissues of COVID-
19 positive donors, the tissue would not be processed 




Certain risk of COVID-19 transmission through cells 
and tissues is possible through isolated cells and 
distribution of such affected cells into specific tissues 
and organs.15 The Laboratory for Tissue Engineering, in 
which human tissues and cells are treated, is constructed, 
organized and maintained to minimize the risk of 
contamination, including cross-contamination. 
Performance, organization and maintenance efficiency 
must be validated and monitored. The performed 
installation meets the design requirements and the 
standards related to cleanrooms and the appropriate 
controlled environment.17 
Keratinocyte cultivations are essential in the treatment 
of patients with burns, and because of that they are 
recognized as tissues for life-saving transplantations.18, 
19 For safe tissue processing, healthcare personnel 
should use a Microbiological Safety Cabinet (MSC) 
class II with installed High-Efficiency Particulate Air 
(HEPA) filters that can remove particle sizes greater 
than 0.3 µm (Figure 2). The laboratory staff members 
should clean and decontaminate work surfaces of the 
MSC, and all equipment used for tissue processing (with 




Tissue and cells storage 
Information about stability of SARS-CoV-2 on different 
surfaces has been published and described that the virus 
was detected after up to 24 hours on cardboard, 72 hours 
 
Figure 2. Tissue processing in a microbiological safety cabinet 
 
 
on plastic and stainless steel surfaces under the 
experimental circumstances tested (controlled relative 
humidity and temperature).15, 22 
Standard practice according to the Guide to The Quality 
of Tissue and Cells for Human Applications is that all 
harvested/collected tissue should be stored in primary 
and secondary containers before distribution for clinical 
use.23 During distribution, we additionally packed 
tissues in a sterile plastic zip lock bag, as a third 
protective layer, which was also treated with 
disinfectant before being placed in the transport 
container. For long-term preservation of human tissue 
such as amniotic membranes or femoral heads, they 
must be stored at -800C (Figures 3, 4). Keratinocytes and 
limbal cells are stored in liquid nitrogen at -1860C. 
According to the ECDC, there is no evidence of virus 
transmission through contaminated packages that are 





We have presented our experience with following 
standard recommendations for safe tissue banking 
procedures during COVID-19, and we have also 
described additional safety measures that we have 
introduced in this period. These additional measures 
were: defined clinical criteria for prevention of COVID-
19 infection for donor selection, tissue procurement, 
processing, and protection of tissue bank personnel and 
monitoring of previously stored tissues for COVID-19. 
These measures might have contributed to the 
prevention of COVID-19 spread, contamination of 
tissue bank facilities, and they have definitely reduced 
the risk for personnel. 
This manuscript provides the necessary information on 
preventive measures during the COVID-19 pandemic 
and the procedures of the TB, healthcare and 
surveillance measures for tissue donors, microbiological 
environmental monitoring of cleanrooms, SOP for the 
safe storage of tissues, cells and all laboratory tests prior 
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Figure 4. Femoral head storage at -80 °C 
 
 
The coronavirus SARS-CoV-2 has imposed increased 
risks in tissue banking with new challenges for 
cleanrooms and for healthcare personnel. Therefore, it is 
very important to keep these risks to a minimum, protect 
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